Other Therapy Areas

Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.

Learn More →

    Home > Events > Reducing study database build time_webinar

    1 min read

    Webinar | Reducing Study Build Time from Weeks to Days

    View Webinar On-Demand

    VIEW ON-DEMAND

    Rapid Database Build for COVID-19 Study Start-Up

    Study start-up and post-go-live protocol amendments can be lengthy, costly, and disruptive to a clinical trial. But with the right technology, data managers can accelerate timelines and overcome these challenges.

    Join Veristat and IBM Watson Health to learn how they were able to start up their COVID-19 trial in just 5 days and post-go-live protocol amendments in just 3 days.

    The discussion will focus on how Veristat used specific IBM Clinical Development features  to achieve these results for the rapid start of a COVID-19 trial.


     

    Attend the Complimentary  Webinar On-Demand:

    Title:  Veristat Reduces Study Build Time from Weeks to Days with IBM Clinical Development

    Date: Thursday, October 08, 2020 (Original Live Date)

    Time: 11:00 AM Eastern Daylight Time

    Duration: 45 minutes

    (You will be brought to the IBM page to register for the download)

    VIEW ON-DEMAND

     


     

    Meet the Speakers:

     

    Ryad RamdaRyad Ramda
    Associate Director, Data Management
    Veristat
     

     
    Walker Bradham
    Walker Bradham
    Offering Manager, IBM Clinical Development
    IBM Watson Health

     

     

    Register for the Webinar Now: 

    (You will be brought to the IBM registration page to download)

    VIEW ON-DEMAND

     

    Share This Event:

       

    11 min read

    Monthly FDA Guidance and Regulatory News Review - September 2026

    This September 2026 regulatory update focuses on FDA’s new guidance on neonatal parenteral nutrition compounding and...

    8 min read

    Monthly FDA Guidance and Regulatory News Review - August 2026

    This August 2026 regulatory update focuses on the FDA finalizing three guidances addressing formal sponsor meetings,...